Form 8-K · Current report
Viatris 8-K, filed Aug 6, 2026
- Filed
- CIK
- 0001792044
- Accession no.
- 0001792044-26-000037
Summary
Viatris reported second-quarter 2026 total revenues of $3.8 billion, up 5% on a reported basis from a year earlier, with a U.S. GAAP net loss of $119 million and adjusted EBITDA of $1.2 billion, and raised the midpoints of its full-year 2026 guidance; CEO Scott A. Smith credited commercial execution, pipeline progress and early benefits of an enterprise-wide strategic review. The company agreed to sell global rights to Tyrvaya to Harrow, Inc. for $30 million upfront plus up to $70 million in contingent commercial milestones, and said the FDA approved its Gwyn Lo contraceptive patch, expected to be commercially available later this year.
Key points
- Second-quarter total revenues were $3.76 billion, up 5% reported and about 3.5% operationally year over year; the U.S. GAAP net loss of $119 million included a $177.8 million non-cash charge for writing down the Tyrvaya intangible to fair value less cost to sell.
- Adjusted EBITDA was $1.19 billion, up 10% reported and 8% operationally, and adjusted EPS was $0.69, up 11% reported and 9% operationally.
- Viatris returned roughly $550 million of capital to shareholders, including about $270 million of share repurchases through early August, and reduced its gross leverage ratio to 2.9x.
- Viatris completed the sale of its equity position in Biocon Limited for pre-tax consideration of about $380 million, finishing monetization of its Biocon Biologics stake for roughly $780 million total.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.